Abstract 5210: Novel SIK2 inhibitors sensitize ovarian and breast cancer to PARP inhibitors

作者
Zhen Lü,Weiqun Mso,Janice M. Santiago‐O’Farrill,Hailing Yang,Lan Pang,Ahmed A. Ahmed,Hariprasad Vankayalapati,Robert C. Bast
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:80 (16_Supplement): 5210-5210
标识
DOI:10.1158/1538-7445.am2020-5210
摘要

Abstract Genomic instability is a recognized hallmark of cancer. Germline mutations in critical DNA-repair and DNA-damage response genes predispose to cancer development, but also create vulnerabilities that can be exploited for cancer therapy. Poly (ADP-ribose) polymerase (PARP) inhibitors are selectively active in cells with homologous recombination deficiency (HRD) caused by mutations in BRCA1, BRCA2, and other DNA repair genes. PARP inhibitors elicit significant responses in ovarian and breast cancers from BRCA1 or BRCA2 mutation carriers. However, many cancers that initially respond to PARP inhibitors eventually develop drug resistance. Thus, it is important to develop new strategies to enhance PARP inhibitor sensitivity and to increase the duration of response. We have identified Salt Induced Kinase 2 (SIK2) inhibitors (ARN3236 and ARN3261) that induce double strand breaks (DSBs) in DNA of HR-competent cells and produce synthetic lethality with multiple PARP inhibitors. SIK2 is an AMP-activated protein kinase (AMPK)-related protein kinase that is required for ovarian cancer cell proliferation and metastasis. SIK2 is overexpressed and correlates with poor prognosis in patients with high-grade serous ovarian carcinoma and triple negative breast cancer. SIK2 inhibition enhances paclitaxel sensitivity in both cancer types. We have demonstrated that olaparib-induced-growth inhibition was significantly enhanced by concurrent treatment with either ARN3236 or ARN3261 in each of 12 ovarian and breast cancer cell lines tested, but not in 3 non-tumorigenic cell lines. Co-administration of olaparib with SIK2 inhibitors suppressed tumor growth and increased the survival of mice with human ovarian (OC316) and breast (MDA-MB-231) cancer xenografts without affecting animal weight. ARN3261 produced little toxicity in preclinical toxicology studies. SIK2 inhibitors decrease the phosphorylation of class-IIa HDAC4/5/7 and abolish class-IIa HDAC 4/5/7-associated transcriptional activity of Myocyte Enhancer Factor 2D (MEF2D). Genome-wide chromatin immunoprecipitation (CHIP) sequencing revealed that SIK2 inhibitors reduce MEF2D binding to regulatory regions with high-chromatin accessibility in DNA repair genes, including FANCD2, EXO1 and XRCC4, resulting in repression of critical genes in DNA DSB repair pathway and induction of apoptosis. In addition, SIK2 inhibitors significantly decreased olaparib-mediated PARP activity and enhanced olaparib-induced cytotoxicity. Together, our data argue that the combination of a SIK2 inhibitor and a PARP inhibitor has the potential to increase the magnitude and duration of PARP inhibitor activity with tolerable toxicity. Use of a SIK2 inhibitor in combination with a PARP inhibitor provides a novel therapeutic strategy for ovarian and triple negative breast cancers with or without BRCA gene mutation. Citation Format: Zhen Lu, Weiqun Mso, Janice M. Santiago-O'Farrill, Hailing Yang, Lan Pang, Ahmed A. Ahmed, Hariprasad Vankayalapati, Robert C. Bast Jr. Novel SIK2 inhibitors sensitize ovarian and breast cancer to PARP inhibitors [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5210.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lx的应助被今天签到了吗采纳,获得10
刚刚
lx的应助被繁荣的飞鸟采纳,获得10
1秒前
852的应助被qcx采纳,获得10
2秒前
2秒前
酷炫亦竹完成签到,获得积分10
5秒前
茅十八完成签到,获得积分10
5秒前
123q完成签到,获得积分10
6秒前
6秒前
6秒前
科研通AI6.2的应助被魏伯安采纳,获得10
6秒前
7秒前
wdyz1234完成签到,获得积分10
8秒前
大模型的应助被lyl采纳,获得30
8秒前
ZZZZZ完成签到,获得积分10
8秒前
科研通AI6.3的应助被胡萝卜卜采纳,获得10
9秒前
慕青的应助被Dlk采纳,获得10
9秒前
wangyu3发布了新的文献求助10
9秒前
9秒前
慕青的应助被奋斗断秋采纳,获得10
10秒前
10秒前
娇娇老师发布了新的文献求助10
11秒前
12秒前
12秒前
法国v刚刚发布了新的文献求助10
13秒前
14秒前
14秒前
风中的善愁完成签到,获得积分0
15秒前
15秒前
大酱踢腿发布了新的文献求助30
15秒前
科研通AI6.3的应助被无所谓采纳,获得30
15秒前
16秒前
16秒前
xyf完成签到 ,获得积分10
17秒前
张维为发布了新的文献求助10
17秒前
kuridan发布了新的文献求助10
18秒前
小徐801发布了新的文献求助10
19秒前
云梦发布了新的文献求助10
19秒前
20秒前
童77欧皇附体完成签到,获得积分10
21秒前
linlin发布了新的文献求助10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191314
求助须知:如何正确求助?哪些是违规求助? 9578210
关于积分的说明 21857267
捐赠科研通 7790624
什么是DOI,文献DOI怎么找? 3436606
关于科研通互助平台的介绍 2560359
邀请新用户注册赠送积分活动 2483305